DUBLIN – A re-evaluation of psychedelic drugs as potential therapies for major depressive disorder, anxiety, post-traumatic stress disorder and other neuropsychiatric conditions has been underway for some time, but this broad effort gained further momentum during 2020, as commercial firms started to raise money at the level needed to enable the field to start moving from small-scale academic studies to the kind of industry-scale trials that will be needed to convince regulators, patients and physicians that these molecules could become viable treatment options.

Beckley Psytech, a UK-based psychedelic medicine company, which has deep ties to the historical Beckley Foundation is dedicated to help patients suffering from psychiatric and neurological disorders. The company works with the vision to integrate clinically validate psychedelic medicines into modern medical practice to help patients all over the world suffering from debilitating conditions.

Q&A with Beckley Psytech Director & Chair of Scientific Advisory Board, Lady Amanda Feilding. Amanda Feilding has been called the ‘hidden hand’ behind the renaissance of psychedelic science. Her contribution to global drug policy reform and to opening the doors to scientific research has been pivotal and widely acknowledged.

Beckley Psytech, a psychedelic medicine company with deep ties to the historical Beckley Foundation, has raised £14m of new equity funding to develop psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases.

We are very excited to announce that Joanna Neill, Professor of Psychopharmacology at the University of Manchester, and Dr Mike Emanuel, former vice president of global clinical operations for EMEA at Johnson & Johnson, are joining our Scientific Advisory Board. As a members of our Board, they will be in esteemed company alongside some of the world’s leading psychedelic and psychiatric researchers, and drug development specialists. Read on to learn about the experience and expertise both Joanna and Mike will bring to our business below.

Q&A with Beckley Psytech CEO Cosmo Feilding-Mellen

We take a deep dive into the stories behind the science

Renowned experts bring decades of experience to Beckley Psytech

Prominent global biotech investors including Canadian businessman Greg Bailey and British entrepreneur Jim Mellon have invested in Beckley Psytech, a new company developing a pipeline of psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases.

World-first phase 1 trial will evaluate efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA)